drugset / Trial / NCT01236118
A Study of LY2439821 in Rheumatoid Arthritis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of LY2439821 subcutaneously administered for 48 weeks in Japanese participants with rheumatoid arthritis who have completed Study I1F-JE-RHAL (NCT01253265).
Timeline
- Start
- 2010-12
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixekizumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | Subcutaneous |
| Subject | Ixekizumab | Monoclonal antibody | 160 mg | Subcutaneous |